Taking the Next Step in MCL: Novel Combos and Immunotherapy Under Study

Published: Friday, Apr 06, 2018
Simon Rule, MD

Simon Rule, MD, PhD
Despite advancements in treatment strategies for mantle cell lymphoma (MCL), patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.1

The potential synergy of these new agents with other treatment strategies, including immunotherapeutic and targeted approaches, is currently being investigated in various clinical trials, with the hope of identifying combinations that will lead to longer responses and improvements in duration of response (DOR) for patients with MCL.

Ibrutinib Combinations

Ibrutinib (Imbruvica) is a potent orally bioavailable inhibitor of BTK that binds irreversibly to the cysteine residue (C481) at the phosphorylation site of BTK, leading to irreversible inactivation and disruption of the signaling pathway from the B-cell receptor (BCR) to the nucleus.4 The BCR signaling pathway plays a crucial role in cell division, differentiation, homing, and survival.5
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication